CN116942663A - 用于治疗hbv的化合物 - Google Patents

用于治疗hbv的化合物 Download PDF

Info

Publication number
CN116942663A
CN116942663A CN202310780889.9A CN202310780889A CN116942663A CN 116942663 A CN116942663 A CN 116942663A CN 202310780889 A CN202310780889 A CN 202310780889A CN 116942663 A CN116942663 A CN 116942663A
Authority
CN
China
Prior art keywords
substituted
oxo
carboxylic acid
naphthyridine
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310780889.9A
Other languages
English (en)
Chinese (zh)
Inventor
J.G.卡塔拉诺
张碧玉
H.D.迪克森
M.R.利弗斯
J.G.韦瑟赫德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN116942663A publication Critical patent/CN116942663A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310780889.9A 2017-10-05 2018-10-05 用于治疗hbv的化合物 Pending CN116942663A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762568633P 2017-10-05 2017-10-05
US62/568633 2017-10-05
US201762570509P 2017-10-10 2017-10-10
US62/570509 2017-10-10
US201862681146P 2018-06-06 2018-06-06
US62/681146 2018-06-06
US201862683859P 2018-06-12 2018-06-12
US62/683859 2018-06-12
PCT/IB2018/057767 WO2019069293A1 (en) 2017-10-05 2018-10-05 CHEMICAL COMPOUNDS
CN201880078910.8A CN111433206B (zh) 2017-10-05 2018-10-05 化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880078910.8A Division CN111433206B (zh) 2017-10-05 2018-10-05 化合物

Publications (1)

Publication Number Publication Date
CN116942663A true CN116942663A (zh) 2023-10-27

Family

ID=64049476

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880078910.8A Active CN111433206B (zh) 2017-10-05 2018-10-05 化合物
CN202310780889.9A Pending CN116942663A (zh) 2017-10-05 2018-10-05 用于治疗hbv的化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880078910.8A Active CN111433206B (zh) 2017-10-05 2018-10-05 化合物

Country Status (25)

Country Link
US (2) US20200255428A1 (hr)
EP (2) EP4180431A1 (hr)
JP (1) JP7248665B2 (hr)
KR (1) KR20200065024A (hr)
CN (2) CN111433206B (hr)
AU (2) AU2018344926A1 (hr)
BR (1) BR112020006456A2 (hr)
CA (1) CA3078312A1 (hr)
CL (1) CL2020000912A1 (hr)
CO (1) CO2020004202A2 (hr)
DK (1) DK3692040T3 (hr)
ES (1) ES2940263T3 (hr)
FI (1) FI3692040T3 (hr)
HR (1) HRP20230274T1 (hr)
HU (1) HUE061380T2 (hr)
IL (1) IL273769A (hr)
LT (1) LT3692040T (hr)
MX (1) MX2020003382A (hr)
PH (1) PH12020550145A1 (hr)
PL (1) PL3692040T3 (hr)
PT (1) PT3692040T (hr)
RS (1) RS64043B1 (hr)
SG (2) SG11202002771XA (hr)
SI (1) SI3692040T1 (hr)
WO (1) WO2019069293A1 (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
CA3017020C (en) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TWI811236B (zh) 2017-08-28 2023-08-11 美商因那塔製藥公司 B型肝炎抗病毒試劑
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2019246427A1 (en) * 2018-06-22 2019-12-26 Arbutus Biopharma Corporation Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
AU2019342750A1 (en) 2018-09-21 2021-04-08 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CA3111046A1 (en) 2018-09-30 2020-04-02 Sunshine Lake Pharma Co., Ltd. Fused tetracyclic compounds and uses thereof in medicine
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
CN111217811B (zh) * 2018-11-26 2024-01-16 广东东阳光药业股份有限公司 稠合三环类化合物及其在药物中的应用
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN113173911A (zh) * 2021-04-20 2021-07-27 梯尔希(南京)药物研发有限公司 吡虫啉代谢物5-羟基吡虫啉的合成方法
WO2023144750A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for treating hepatitis b virus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899508B (zh) * 2014-01-30 2017-07-04 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物
WO2015173164A1 (en) * 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) * 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
JP6435054B2 (ja) * 2015-02-11 2018-12-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染の治療及び予防のための新規2−オキソ−6,7−ジヒドロベンゾ[a]キノリジン−3−カルボン酸誘導体
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2018047109A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
KR102522060B1 (ko) * 2016-11-07 2023-04-14 아뷰터스 바이오파마 코포레이션 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
CN106810548B (zh) * 2017-01-13 2019-02-15 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物
CN108727378A (zh) * 2017-04-19 2018-11-02 银杏树药业(苏州)有限公司 新型异喹啉类化合物及其医药用途

Also Published As

Publication number Publication date
CO2020004202A2 (es) 2020-04-24
PL3692040T3 (pl) 2023-04-17
EP3692040A1 (en) 2020-08-12
SG10202111648YA (en) 2021-11-29
RU2020118375A (ru) 2021-11-09
HRP20230274T1 (hr) 2023-04-28
JP2020536110A (ja) 2020-12-10
US20220144834A1 (en) 2022-05-12
AU2021203650B9 (en) 2022-10-06
PH12020550145A1 (en) 2021-01-04
JP7248665B2 (ja) 2023-03-29
HUE061380T2 (hu) 2023-06-28
CN111433206B (zh) 2023-07-07
AU2021203650A1 (en) 2021-07-01
RU2020118375A3 (hr) 2022-04-13
IL273769A (en) 2020-05-31
SI3692040T1 (sl) 2023-05-31
AU2018344926A1 (en) 2020-04-16
US20200255428A1 (en) 2020-08-13
WO2019069293A1 (en) 2019-04-11
CN111433206A (zh) 2020-07-17
EP4180431A1 (en) 2023-05-17
EP3692040B1 (en) 2022-12-28
CA3078312A1 (en) 2019-04-11
CL2020000912A1 (es) 2021-02-19
FI3692040T3 (fi) 2023-03-29
ES2940263T3 (es) 2023-05-04
DK3692040T3 (da) 2023-03-13
LT3692040T (lt) 2023-04-25
PT3692040T (pt) 2023-04-03
KR20200065024A (ko) 2020-06-08
AU2021203650B2 (en) 2022-09-08
BR112020006456A2 (pt) 2020-10-06
MX2020003382A (es) 2020-10-05
RS64043B1 (sr) 2023-04-28
SG11202002771XA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CN111433206B (zh) 化合物
JP6506845B2 (ja) B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
CN107624113B (zh) 作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物
CN104837829B (zh) 抑制剂化合物
EP3478686A1 (en) Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN109311846B (zh) 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
TWI721104B (zh) 6‐芳基或6‐雜芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物
CN112585118A (zh) 乙型肝炎衣壳装配调节剂
JP2016505021A (ja) Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
KR20200081436A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 화합물
CA3092770A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN114144410A (zh) 多芳基脲衍生物及其在治疗肌肉疾病中的用途
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
RU2800292C2 (ru) Химические соединения
WO2024088407A1 (zh) 并环含氮化合物、其中间体、制备方法和应用
AU2015201122B2 (en) Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
EP4358954A1 (en) Cdk2 inhibitors and methods of using the same
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
CN114805341A (zh) 一类芳杂环类化合物及其制备方法和用途
CN116390917A (zh) Mrgx2拮抗剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination